Cost Effectiveness of Moderate to Severe Psoriasis Therapy with Etanercept and Ustekinumab in the United States
Purchase on Springer.com
$49.95 / €39.95 / £34.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Limited information is available on the cost effectiveness of ustekinumab and alternative biologic treatments in a United States (US) setting. Given the recent head-to-head clinical trial study of ustekinumab and etanercept, an economic model comparing the two treatments can be constructed. Etanercept and ustekinumab are indicated for the treatment of chronic moderate to severe plaque psoriasis in adult patients who are candidates for phototherapy or systemic therapy.
Clinical trials have evaluated the efficacy of ustekinumab, an anti-cytokine biologic, for the treatment of moderate to severe psoriasis. This study evaluated the cost effectiveness of ustekinumab compared with etanercept from a US societal perspective.
A Markov model was constructed to simulate the incremental cost per quality-adjusted life-year (QALY) gained every 12 weeks over a base-case 3-year time horizon. A hypothetical patient cohort was based on the characteristics of the phase III Active Comparator Psoriasis Trial (ACCEPT). The main outcome measures were costs and QALYs, which were estimated from the US societal perspective. Costs, utilities, treatment strategy, and resource use estimates were obtained from relevant literature. All costs were adjusted to 2011 US dollars. A 3 % annual discount rate was applied to costs and QALYs. Incremental cost-effectiveness ratios were in US dollars per QALY gained.
For the base-case 3-year time horizon, the incremental cost-effectiveness ratio comparing ustekinumab 90 mg with etanercept 50 mg was US$384,401 per QALY gained. Ustekinumab 45 mg dominates etanercept 50 mg for the same time horizon. These results were robust to sensitivity analyses involving treatment strategy, transition probabilities, valuing outcomes, and resource use and costs. The probabilistic sensitivity analysis suggests ustekinumab 90 mg has a minimal (4 %) chance of being cost effective compared with etanercept 50 mg at a willingness-to-pay threshold of US$150,000 per QALY improvement. For the same threshold, ustekinumab 45 mg has a high (88 %) chance of being cost effective compared with etanercept 50 mg.
Under typical US willingness-to-pay cutoffs, ustekinumab 90 mg is not cost effective compared with etanercept 50 mg therapy in moderate to severe psoriasis patients for the base-case 3-year time horizon. Ustekinumab 45 mg dominates etanercept 50 mg therapy for an equivalent patient psoriasis severity and time horizon.
- Nestle F, Kaplan D, Barker J. Mechanisms of disease psoriasis. N Engl J Med. 2009;361:496–509. CrossRef
- Menter A, Gottlieb A, Feldman S, Van Voorhees A, Leonardi C, Gordon K, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–50. CrossRef
- Menter A, Korman NJ, Elmets C, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis Section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65:137–74. CrossRef
- Frankel A, Lebwohl M. Treatment options for psoriasis patients who have failed at least one biological therapy. Adv Psor Inflamm Skin Dis 2010;1(4):119–24.
- Leonardi C, Kimball A, Papp K, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet. 2008;371:1665–74. CrossRef
- Papp K, Langley R, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet. 2008;371:1675–84. CrossRef
- Griffiths C, Strober B, van de Kerkhof P, et al. Comparison of ustekinumab and etanercept for moderate to severe psoriasis. N Engl J Med. 2010;362:118–28. CrossRef
- Miller DW, Feldman SR. Cost-effectiveness of moderate to severe psoriasis treatment. Expert Opin Pharmacother. 2006;7(2):157–67. CrossRef
- Gold M, Siegel J, Russell L, et al., editors. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996.
- Neumann PJ, Rosen AB, Weinstein MC. Medicare and cost-effectiveness analysis. N Engl J Med. 2005;353:1516–22. CrossRef
- Detsky AS, Laupacis A. Relevance of cost-effectiveness analysis to clinicians and policy makers. JAMA. 2007;298:221–4. CrossRef
- Martin S, Feldman SR, Augustin M, Szapary P, Schenkel B. Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis. J Dermatol Treat. 2011;22:138–43. CrossRef
- Pan F, Brazier N, Shear N, et al. Cost utility analysis based on a head-to-head phase 3 clinical trial comparing ustekinumab and etanercept in patients with moderate to severe plaque psoriasis: a Canadian perspective. Value Health. 2011;14:652–6. CrossRef
- Brazier J, Ratcliffe J, Salomon JA, et al., editors. Measuring and valuing health benefits for economic evaluation. New York: Oxford University Press; 2007.
- Report of the Commission on Macroeconomics and Health, Macroeconomics and Health: Investing in Health for Economic Development, World Health Organization. 2001.
- United States of America, Central Intelligence Agency, The World Factbook. https://www.cia.gov/library/publications/the-world-factbook/geos/us.html. Accessed September 2011.
- Carlin CS, Feldman SR, Krueger JG, Menter A, Krueger GG. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol. 2004;50:859–66. CrossRef
- Gelfand J, Troxel A, Lewis J, et al. The risk of mortality in patients with psoriasis. Arch Dermatol. 2007;143(12):1493–9. CrossRef
- Woolacott N, Hawkins N, Mason A, Kainth A, Khadjesari Z, Bravo Vergel Y, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess. 2006;10(46):1–233, i–iv.
- Sterry W, Barker J, Boehncke WH, Bos JD, Chimenti S, Christophers E, et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Dermatol. 2004;69:3–17. CrossRef
- Griffiths CE, Dubertret L, Ellis CN, Finlay AY, Finzi AF, Ho VC, et al. Ciclosporin in psoriasis clinical practice: an international consensus statement. Br J Dermatol. 2004;150:11–23. CrossRef
- Pariser DM, et al. Integrated safety analysis: short- and long-term safety profiles of etanercept in patients with psoriasis. J Am Acad Dermatol. 2012;67(2):245–56. CrossRef
- Reich K, et al. An update on long-term safety experience of ustekinumab: results from the psoriasis clinical development program with up to four years of follow-up. J Drugs Dermatol. 2012;11(3):300–12.
- Etanercept prescribing indications and medication guide. www.enbrel.com. Accessed July 2011.
- Ustekinumab prescribing indications and medication guide. www.stelarainfo.com. Accessed July 2011.
- Schmitt J, Meurer M, Klon M, et al. Assessment of health states utilities of controlled and uncontrolled psoriasis and atopic eczema: a population-based study. Br J Dermatol. 2008;158:351–9. CrossRef
- Currie C, Conway P. Evaluation of the association between EQ5D utility and dermatology life quality index (DLQI) score in patients with psoriasis. Value Health. 2007;10(6):A470–1. CrossRef
- Krueger GG, et al. Position paper. Two considerations for patients with psoriasis: What defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol. 2000;43:281–5. CrossRef
- Katugampola R, Lewis V, Finlay A. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis. Br J Dermatol. 2007;156:945–50. CrossRef
- Nelson AA, Pearce DJ, Fleischer AB, Balkrishnan R, Feldman SR. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. J Am Acad Dermatol. 2008;58:125–35. CrossRef
- Beck J, Kassirer J, Pauker S. A convenient approximation of life expectancy (the “DEALE”) I. Validation of the method. Am J Med. 1982;73:883–8. CrossRef
- Beck J, Pauker S, Gottlieb J, et al. A convenient approximation of life expectancy (the “DEALE”) II. Use in medical decision-making. Am J Med. 1982;73:889–97. CrossRef
- Papp K, Tyring S, Lahfa M, et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol. 2005;152:1304–12. CrossRef
- Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomized phase III trial. Lancet. 2006;367:29–35. CrossRef
- Elewski B, Leonardi C, Gottlieb AB, Strober BE, Simiens MA, Dunn M, et al. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis. Br J Dermatol. 2007;156:138–42. CrossRef
- Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med. 2003;349:2014–22. CrossRef
- Hankin CS, Feldman SR, Szczotka A, Stinger RC, Fish L, Hankin DL. A cost comparison of treatments of moderate to severe psoriasis. Drug Benefit Trends. 2005;17:200–14.
- Centers for Medicare and Medicaid Services, 2011 Medicare Part B Drug Average Sales Price. http://www.cms.gov/McrPartBDrugAvgSalesPrice/01a18_2011ASPFiles.asp#TopOfPage. Accessed July 2011.
- Drugstore.com. http://www.drugstore.com. Accessed July 2011.
- Centers for Medicare and Medicaid Services, Physician Fee Schedule. https://www.cms.gov/apps/physician-fee-schedule/license-agreement.aspx. Accessed July 2011.
- National Compensation Survey, All United States, December 2009–January 2011. http://www.bls.gov/ncs/ocs/sp/nctb1476.pdf. Accessed July 2011.
- Bureau of Labor Statistics, United States Department of Labor. www.bls.gov/data/. Accessed July 2011.
- Kivitz A, Cohen S, Dowd JE, Edwards W, Thakker S, Wellborne FR, et al. Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: the TOUCH Trial. Clin Ther. 2007;28(10):1619–29.
- Yu A, Tang J, Xie J, et al. Economic burden of psoriasis compared to the general population and stratified by disease severity. Curr Med Res Opin. 2009;25(10):2429–38. CrossRef
- Crown WH, Bresnahan BW, Orsini LS, et al. The burden of illness associated with psoriasis: cost of treatment with systemic therapy and phototherapy in the US. Curr Med Res Opin. 2004;20(12):1929–36. CrossRef
- Kimball AB, Guerin A, Tsaneva M, et al. Economic burden of comorbidities in patients with psoriasis is substantial. J Eur Acad Dermatol Venereol. 2011;25:157–63. CrossRef
- Fowler JF, Duh MS, Rovba L, et al. The impact of psoriasis in health care costs and patient work loss. J Am Acad Dermatol. 2008;59(5):772–80. CrossRef
- Krueger GG, Langley RG, Finlay AY, et al. Patient-reported outcomes of psoriasis improvement with etanercept therapy: results of a randomized phase III trial. Br J Dermatol. 2005;153:192–9. CrossRef
- Chilton F, et al. Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. Musculoskelet Care. 2008;6(1):1–14. CrossRef
- Report: US Census Bureau, Statistical Abstract of the United States: 2011. Source: US National Center for Health Statistic. National Vital Statistics Reports, Deaths: Final Data for 2007. Vo. 58, No. 19, May 2010.
- Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, Jahreis A. Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. Arch Dermatol. 2007;143:719–26. CrossRef
- Anis AH, Bansback N, Sizto S, Gupta SR, Willian MK, Feldman SR. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States. J Dermatol Treat. 2011;22:65–74. CrossRef
- Moore A, Gordon KB, Kang S, Gottlieb A, Freundlich B, Xia A, et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. J Am Acad Dermatol. 2007;56:598–603. CrossRef
- Ortonne JP, Griffiths CEM, Dauden E, Strohal R, Robertson D, Pederson R, et al. Efficacy and safety of continuous versus paused etanercept treatment in patients with moderate to severe psoriasis over 54 weeks: the CRYSTEL study. Expert Rev Dermatol. 2008;3(6):657–65. CrossRef
- Cost Effectiveness of Moderate to Severe Psoriasis Therapy with Etanercept and Ustekinumab in the United States
Volume 31, Issue 9 , pp 823-839
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors